<DOC>
	<DOCNO>NCT01038128</DOCNO>
	<brief_summary>The primary objective 13-week clinical trial test hypothesis treatment Memantine significantly improve symptom suffer either bulimia nervosa , purge type suffer body dysmorphic disorder .</brief_summary>
	<brief_title>An Open Label Trial Memantine Treatment Bulimia Nervosa Body Dysmorphic Disorder</brief_title>
	<detailed_description>The primary objective clinical trial test hypothesis treatment Memantine , anti-glutamatergic drug , significantly improve core symptom suffer either bulimia nervosa , purge type suffer body dysmorphic disorder . We test hypothesis perform 13-week open label study investigate use memantine , dose 10-40mg daily , treatment patient either bulimia nervosa body dysmorphic disorder . Improvement patient bulimia nervosa assess use Frequency binge eat vomit record diary card , Eating Disorder Evaluation ( EDE ) , Yale-Brown-Cornell Eating Disorders Scale ( YBC-EDS ) . Improvement patient body dysmorphic disorder assess use Yale-Brown-Cornell Eating Disorders Scale ( YBC-EDS ) Brown Assessments Beliefs Scale . In addition group also receive Clinical Global Impression ( CGI ) Severity Improvement Scales ( clinician rat ) , Patient Global Impression Improvement ( PGI-Improvement ) , Montgomery Asberg Depression Rating Scale ( MADRS ) , Hamilton Anxiety Rating Scale ( HAM-A ) , Barratt Impulsiveness Scale ( BIS ) , Version 11 , Sheehan Disability Scale ( SDS ) , Columbia Suicide Severity Rating Scale ( C-SSRS ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Bulimia Nervosa</mesh_term>
	<mesh_term>Body Dysmorphic Disorders</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Bulimia Nervosa Participants must meet DSMIV criterion current diagnosis bulimia nervosa determine Structured Clinical Interview DSMIV ( SCID ) Eating Disorder Examination ( EDE ) . Participants must report average 3 binge vomit episode per week 2week period prior screen visit . Male Female 18 65 year age , inclusive . Female participant must : postmenopausal least one year , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization , abstinence agree continue abstinence use one acceptable method contraception enumerate sexual activity commence ) entry throughout study ; negative serum pregnancy test screen visit . Participants must observe designate washout period least seven day period equal five halflives prohibit medication . Participants must able take oral medication , adhere medication regimen , willing return regular visit . Participants must able willing read comprehend write instruction comprehend complete scale questionnaire require protocol . Participants must sign informed consent document indicate understand purpose procedure require study willing participate study . Body Dysmorphic Disorder Inclusion criterion participant body dysmorphic disorder identical bulimia nervosa , follow difference first two criterion : Participants must meet DSMIV criterion current diagnosis body dysmorphic disorder determine SCID . Participants must exhibit score ≥ 20 Body Dysmorphic Disorder Version Yale Brown Obsessive Compulsive Scale ( BDDYBOCS ) score ≥ 5 first three item BDDYBOCS , item assess DSMIV criterion Body Dysmorphic Disorder . Exclusion Criteria Bulimia Nervosa Body Dysmorphic Disorder : Participants lifetime diagnosis schizophrenia , psychotic disorder , bipolar disorder define DSMIV support SCID . Participants clinically significant current depression , investigator ' judgment , might require intervention either pharmacological nonpharmacological therapy major depressive disorder course study . Participants judge clinically suicidal homicidal risk study physician . Participants meet DSMIV criterion form substance dependence abuse ( exception nicotine caffeine dependence ) within 3 month prior screen visit . Participants meet DSMIV criterion anorexia nervosa within 3 month prior screen visit . Participants current DSMIV diagnosis organic mental disorder . Participants begin receive formal psychotherapy ( cognitivebehavioral therapy , interpersonal therapy selfguided cognitivebehavioral therapy ) bulimia nervosa within 6 month prior screen visit . Participants display positive urine screen drug abuse ( phencyclidine , cocaine , amphetamine , tetrahydrocannabinol , opiates ) screen visit . Participants previously receive memantine reason . Participants receive investigational medication within 30 day screen visit . Participants pregnant lactating . Participants body mass index ( BMI ) less 18.5 great 35 . Participants abuse ipecac method purge within past 2 year . Participants exhibit serum potassium level le 3.0 mEq/L . Participants thyroidstimulating hormone concentration outside range 0.55.0 lU/mL . Participants clinically significant unstable medical condition Participants opinion investigator enrol study precaution , warning contraindication section prescribe information memantine Employees investigator , individual direct involvement study direction study investigator , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Bulimia nervosa</keyword>
	<keyword>Bulimia</keyword>
	<keyword>Body dysmorphic disorder</keyword>
	<keyword>Eating disorder</keyword>
	<keyword>Body image</keyword>
	<keyword>Binge eating</keyword>
	<keyword>purge</keyword>
</DOC>